ROCKVILLE, Md., March 29 /PRNewswire-FirstCall/ -- EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported results for the three months and twelve months ended December 31, 2009.
For fiscal year 2009, revenues were $5.3 million versus $7.5 million for 2008. For the year ended December 31, 2009, the Company reported a net loss of ($9.2 million) or ($0.11) per share, versus ($24.9 million), or ($0.29) per share, for fiscal year 2008. As of December 31, 2009, the Company had cash and short-term investments of approximately $6.4 million.
Kathy R. Wehmeir-Davis, Principal Accounting Officer, commented, "Focusing our efforts and resources on the clinical development of our lead product candidate, ENMD-2076, resulted in a reduction in R&D expenses to $7.9 million in 2009 from $20.7 million in 2008. With no plans to initiate further trials for our other programs, we anticipate that R&D expenses for the compounds currently in clinical trials will continue to decrease as patients come off current studies. However, we intend to commence Phase 2 studies with ENMD-2076 in the second quarter, which we expect will increase R&D expenses in 2010."
Further up-to-date information regarding the Company, including our most recent Form 10-K filing and Letter from the Executive Chairman, can be found on our web site at www.entremed.com.
EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing primarily ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer. ENMD-2076 is currently in Phase 1 studies in advanced cancers, multiple myeloma, and leukemia. Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; the failure to consummate a transaction to monetize the royalty stream for any reason, including our inability to obtain the required third-party consents; declines in actual sales of Thalomid(R) resulting in reduced revenues; risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).
Photo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.comEntreMed, Inc.
